Publication Date
| In 2025 | 0 |
| Since 2024 | 0 |
| Since 2021 (last 5 years) | 0 |
| Since 2016 (last 10 years) | 0 |
| Since 2006 (last 20 years) | 3 |
Descriptor
| Antisocial Behavior | 3 |
| Autism | 3 |
| Children | 3 |
| Pervasive Developmental… | 3 |
| Check Lists | 2 |
| Drug Therapy | 2 |
| Symptoms (Individual… | 2 |
| Adolescents | 1 |
| Behavior Modification | 1 |
| Behavior Problems | 1 |
| Caregivers | 1 |
| More ▼ | |
Author
Publication Type
| Journal Articles | 3 |
| Reports - Research | 3 |
Education Level
Audience
Location
Laws, Policies, & Programs
Assessments and Surveys
| Aberrant Behavior Checklist | 3 |
What Works Clearinghouse Rating
Peer reviewed
Direct linkErickson, Craig A.; Wink, Logan K.; Early, Maureen C.; Stiegelmeyer, Elizabeth; Mathieu-Frasier, Lauren; Patrick, Vanessa; McDougle, Christopher J. – Journal of Autism and Developmental Disorders, 2014
Rationale: An excitatory/inhibitory (E:I) imbalance marked by enhanced glutamate and deficient gamma-aminobutyric acid (GABA) neurotransmission may contribute to the pathophysiology of autism spectrum disorders (ASD). Objectives: We report on the first single-blind placebo lead-in trial of acamprosate, a drug with putative mechanisms restoring E:I…
Descriptors: Autism, Pervasive Developmental Disorders, Drug Therapy, Metabolism
Siegel, Matthew; Milligan, Briana; Stein, Hannah; Teer, Olivia; Smith, Kahsi A. – Journal of Intellectual Disabilities, 2013
To advance clinical care and research in children with intellectual disability and autism there is a growing need for efficient means to measure behavioral severity and response to treatment. The objective of this study was to assess the feasibility of telephone administration of the Aberrant Behavior Checklist-Irritability Subscale (ABC-I). The…
Descriptors: Telephone Surveys, Antisocial Behavior, Check Lists, Feasibility Studies
Pandina, Gahan J.; Bossie, Cynthia A.; Youssef, Eriene; Zhu, Young; Dunbar, Fiona – Journal of Autism and Developmental Disorders, 2007
Subgroup analysis of children (5-12 years) with autism enrolled in an 8-week, double-blind, placebo-controlled trial of risperidone for pervasive developmental disorders. The primary efficacy measure was the Aberrant Behavior Checklist-Irritability (ABC-I) subscale. Data were available for 55 children given risperidone (n = 27) or placebo (n =…
Descriptors: Autism, Drug Therapy, Children, Behavior Modification
